Tyra Biosciences identified 60 mg once-daily dabogratinib as a potential dose after a 79% overall response rate in 11 of 14 evaluable SURF302 participants. The result supports planned registrational development in FGFR3-altered bladder cancer, while additional studies produced an early complete response and cleared a fifth dose level.
Key Highlights
- Grade 3 treatment-emergent adverse events occurred in 3 participants in the 60 mg cohort, representing 14%.
- The first SURF303 participant achieved a complete response after three months at 60 mg once daily.
- BEACH301 cleared its fifth dose level without safety signals in its safety sentinel cohort.
Tyra Biosciences, Inc. (NASDAQ: TYRA) identified oral dabogratinib at 60 mg once daily as a potential dose for its planned registrational adjuvant strategy in a bladder cancer population with FGFR3 alterations. SURF302 produced an overall response rate of 79%, or 11 of 14 evaluable participants, at that dose. The filing also covered an initial complete response in SURF303 and clearance of a fifth dose level in BEACH301.
SURF302 Response Data
Across the 60 mg and lower-dose once-daily cohorts, participants were evaluable for efficacy after receiving treatment and completing at least the month 3 disease assessment. The 60 mg cohort recorded a 79% overall response rate, with 11 of 14 participants responding. Complete responses accounted for 57%, or 8 of 14 participants, at the three-month assessment and 64%, or 9 of 14, on best overall response. Partial responses represented 21%, or 3 of 14 participants, at three months and 14%, or 2 of 14, on best overall response. The lower-dose cohort produced a 67% overall response rate, or 8 of 12 participants. Complete responses represented 33%, or 4 of 12, while partial responses also represented 33%, or 4 of 12. Among participants with single-marker lesions, the 60 mg cohort produced a 100% overall response rate, or 8 of 8 participants. Across the pooled lower-dose and 60 mg groups, the overall response rate was 94%, or 15 of 16 participants. The first participant remained in complete response at 12 months and continued treatment at 14 months.
Dabogratinib Safety And Dose Planning
Initial safety findings covered the 60 mg and lower-dose cohorts. Most treatment-emergent adverse events were lower grade. Grade 3 events affected 3 participants, or 14%, at 60 mg and 2 participants, or 9%, at the lower dose. Grade 3 treatment-related adverse events occurred in 2 of 44 participants, or 4.5%, across both cohorts. Both occurred at the lower dose, while none occurred at 60 mg. Transaminase-related treatment-emergent adverse events occurred at a frequency below 10%, while fatigue, diarrhea and dry eye were the most frequently reported events at 60 mg. Diarrhea was generally lower grade, temporary and limited. Preliminary exposure-response analysis showed an 86% overall response rate, or 12 of 14 participants, among those above the target steady-state exposure threshold of 2500 nanograms per hour per milliliter. Tyra described continued enrollment at 60 mg and evaluation of a higher-dose once-daily cohort for the ablative setting.
SURF303 And BEACH301 Updates
No treatment-emergent adverse events were observed for that participant. BEACH301 cleared its fifth dose level in the safety sentinel cohort. The phase-two study is evaluating oral dabogratinib in children with achondroplasia through dose escalation and dose expansion, and the fifth dose level had no observed safety signals. Initial or interim clinical outcomes may change as enrollment continues, data undergoes more comprehensive review and additional patient follow-up becomes available.






Please wait processing your request...